Prognostic value of matrix metalloproteinase-2 protein and matrix metalloproteinase-9 protein in colorectal cancer: a meta-analysis.
Colorectal cancer (CRC)
Matrix metalloproteinase-2 (MMP-2)
Matrix metalloproteinase-9 (MMP-9)
Meta-analysis
Prognosis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
23
03
2024
accepted:
06
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) are critical components of the extracellular matrix (ECM) in colorectal cancer (CRC). We aimed to evaluate the prognostic value of MMP-2 and MMP-9 in patients with CRC. We performed a meta-analysis of cohort studies with available data on the effect of MMP-2 and MMP-9 expression on both disease-free survival (DFS) and overall survival (OS) by the risk ratios (RRs) with their 95% confidence intervals (CIs). Studies were subgrouped based on the different tissue types, including cancer tissue and normal tissue, and the subgroup effect of MMP expression in different tissues was analyzed through meta-regression. To ensure the quality and reduce the risk of bias, the Newcastle‒Ottawa Scale (NOS) was used to assess the included studies. A sensitivity analysis was randomly performed to assess the potential impact of each study on our results. Eighteen trials were selected (Table 1) and included a total of 3944 patients. According to our primary meta-analysis, the expression of MMP-2 was significantly associated with a decrease in OS (RR = 1.75, 95% CI = 1.34 to 2.29, P < 0.001) and DFS (RR = 2.62, 95% CI = 1.25 to 5.49, P < 0.001), and the expression of MMP-9 was not significantly associated with a decrease in OS (RR = 1.48, 95% CI = 0.97 to 2.24, P = 0.069) or DFS (RR = 1.60, 95% CI = 0.87 to 2.94, P = 0.133). According to the subgroup analysis of MMPs in different tissues, high MMP-2 expression in cancer tissue (RR = 1.90, 95% CI = 1.29 to 2.79) and normal tissue (RR = 1.59, 95% CI = 1.17 to 2.17) were significant indicators of poor OS. High MMP-2 expression in cancer tissue was significant indicator of poor DFS (RR = 2.12, 95% CI = 1.09 to 4.11). MMP-9 expression was also associated with poor OS (RR = 1.40, 95% CI = 0.85 to 2.29), but the difference in OS between the high and low expression groups was not statistically significant. High MMP-2 expression, especially in cancer tissue, is significantly associated with both poor DFS and poor OS in patients with CRC. High MMP-9 expression tended to indicate a poor prognosis of CRC but the correlation was not significant.
Identifiants
pubmed: 39210344
doi: 10.1186/s12885-024-12775-9
pii: 10.1186/s12885-024-12775-9
pmc: PMC11360742
doi:
Substances chimiques
Matrix Metalloproteinase 9
EC 3.4.24.35
Matrix Metalloproteinase 2
EC 3.4.24.24
MMP9 protein, human
EC 3.4.24.35
Biomarkers, Tumor
0
MMP2 protein, human
EC 3.4.24.24
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1065Informations de copyright
© 2024. The Author(s).
Références
Cell Death Dis. 2020 Sep 17;11(9):767
pubmed: 32943603
Cancer Biomark. 2017;19(1):57-64
pubmed: 28269751
Sci Rep. 2023 Oct 2;13(1):16565
pubmed: 37783745
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Sci. 2009 May;100(5):852-8
pubmed: 19445018
Br J Cancer. 2012 Apr 24;106(9):1495-8
pubmed: 22472880
Front Mol Biosci. 2022 Sep 29;9:896099
pubmed: 36250005
Molecules. 2022 Mar 27;27(7):
pubmed: 35408561
Cell Adh Migr. 2019 Dec;13(1):273-284
pubmed: 31293204
Pathol Res Pract. 2015 Jan;211(1):71-7
pubmed: 25446246
Chin Med J (Engl). 2011 Jul;124(14):2132-5
pubmed: 21933615
Int J Cancer. 2007 Aug 15;121(4):714-23
pubmed: 17455256
J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27
pubmed: 12235282
Future Oncol. 2016 Feb;12(3):323-31
pubmed: 26814712
Croat Med J. 2008 Oct;49(5):636-42
pubmed: 18925697
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Oncol Rep. 2020 Oct;44(4):1671-1685
pubmed: 32945508
Int J Colorectal Dis. 2005 May;20(3):245-52
pubmed: 15592677
Oncology. 2021;99(3):144-160
pubmed: 33027796
Cancer Chemother Pharmacol. 2006 May;57(5):577-83
pubmed: 16133529
CA Cancer J Clin. 2022 Jul;72(4):372-401
pubmed: 35472088
Breast Cancer Res Treat. 2004 Nov;88(1):75-85
pubmed: 15538048
Int J Colorectal Dis. 2001 Jun;16(3):133-40
pubmed: 11459286
Molecules. 2021 Dec 04;26(23):
pubmed: 34885950
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Cell Biochem Biophys. 2015 Sep;73(1):253-9
pubmed: 25726157
J Clin Pathol. 2002 Oct;55(10):758-62
pubmed: 12354802
Aging (Albany NY). 2017 Mar 18;9(3):914-931
pubmed: 28316326
J Cancer Res Clin Oncol. 2012 Dec;138(12):2035-44
pubmed: 22806308
J Gastrointest Cancer. 2009;40(3-4):91-7
pubmed: 19921474
Cancer Res. 2010 Jan 15;70(2):792-801
pubmed: 20068187
Expert Opin Drug Discov. 2018 Jan;13(1):75-87
pubmed: 29088927
J Hematol Oncol. 2022 Jul 16;15(1):95
pubmed: 35842707
FASEB J. 1999 May;13(8):781-92
pubmed: 10224222
Front Oncol. 2022 Jun 23;12:891652
pubmed: 35814435
Gastroenterology. 2011 Oct;141(4):1381-92
pubmed: 21723221
Dis Colon Rectum. 2007 Nov;50(11):1887-98
pubmed: 17882488
Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):840-8
pubmed: 21968416
Hum Pathol. 2007 Nov;38(11):1603-10
pubmed: 17669467
Br J Cancer. 2008 Jun 3;98(11):1820-3
pubmed: 18506186
Oncologist. 2000;5(2):108-14
pubmed: 10794801
Crit Rev Oncol Hematol. 2022 Jul;175:103712
pubmed: 35588938